Europe:+32-2-535-7543
Asia: +65-6223-2436
Int'l: +1-860-674-8796
US: +1-866-353-3335
  • Japanese
  • Korean
  • Chinese
Cover Image

Osteoarthritis (OA) Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, "Osteoarthritis (OA) Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Osteoarthritis Pain Therapeutics market. The report identifies the key trends shaping and driving the global Osteoarthritis Pain Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Osteoarthritis Pain Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Osteoarthritis Pain Therapeutics market. Its scope includes -

  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Osteoarthritis Pain Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
  • Analysis of the current and future competition in the seven key countries Osteoarthritis Pain Therapeutics market.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Osteoarthritis Pain Therapeutics market.
  • Analysis of key recent licensing and partnership agreements in Osteoarthritis Pain Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Osteoarthritis Pain Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Osteoarthritis Pain Therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What's the next big thing in the global Osteoarthritis Pain Therapeutics market landscape? - Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Osteoarthritis Pain Therapeutics - Introduction

  • 2.1. Disease Overview
    • 2.1.1. Classification of Osteoarthritis
    • 2.1.2. Types of Osteoarthritis
    • 2.1.3. Osteoarthritis Pain
  • 2.2. Epidemiology
    • 2.2.1. Prevalence
  • 2.3. Quality of Life
  • 2.4. Etiology
  • 2.5. Signs and Symptoms
  • 2.6. Diagnosis
    • 2.6.1. Physical Examination
    • 2.6.2. Radiological Examination
    • 2.6.3. Laboratory Test
  • 2.7. Pathophysiology
    • 2.7.1. Progression of the Disease
  • 2.8. Treatment and Management Options
    • 2.8.1. Pharmacological treatment
  • 2.9. Referral Pathway
  • 2.10. GlobalData Pipeline Report Guidance

3. Osteoarthritis Pain Therapeutics - Market Characterization

  • 3.1. Overview
  • 3.2. Osteoarthritis Pain Therapeutics Market Size (2006-2011) - Global
  • 3.3. Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) - Global
  • 3.4. Osteoarthritis Pain Therapeutics Market Size (2006-2011) - The US
  • 3.5. Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) - The US
  • 3.6. Osteoarthritis Pain Therapeutics Market Size (2006-2011) - France
  • 3.7. Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) - France
  • 3.8. Osteoarthritis Pain Therapeutics Market Size (2006-2011) - Germany
  • 3.9. Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) - Germany
  • 3.10. Osteoarthritis Pain Therapeutics Market Size (2006-2011) - Italy
  • 3.11. Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) - Italy
  • 3.12. Osteoarthritis Pain Therapeutics Market Size (2006-2011) - Spain
  • 3.13. Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) - Spain
  • 3.14. Osteoarthritis Pain Therapeutics Market Size (2006-2011) - The UK
  • 3.15. Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) - The UK
  • 3.16. Osteoarthritis Pain Therapeutics Market Size (2006-2011) - Japan
  • 3.17. Osteoarthritis Pain Therapeutics Market Forecast (2011-2019) - Japan
  • 3.18. Drivers and Barriers for the Osteoarthritis Pain Therapeutics Market
    • 3.18.1. Drivers for the Osteoarthritis Pain Therapeutics Market
    • 3.18.2. Barriers for the Osteoarthritis Pain Therapeutics Market
  • 3.19. Opportunity and Unmet Need Analysis
  • 3.20. Key Takeaway

4. Osteoarthritis Pain Therapeutics - Competitive Assessment

  • 4.1. Overview
  • 4.2. Strategic Competitor Assessment
  • 4.3. Product Profiles for the Major Marketed Products in the Osteoarthritis Pain Therapeutics Market
    • 4.3.1. Celebrex (celecoxib)
    • 4.3.2. Voltaren Gel (diclofenac sodium)
    • 4.3.3. Hyalgan (sodium hyaluronate)
    • 4.3.4. Cymbalta (duloxetine)
    • 4.3.5. Synvisc (hylan G-F 20)
  • 4.4. Key Takeaway

5. Osteoarthritis Pain Therapeutics - Pipeline Assessment

  • 5.1. Overview
  • 5.2. Strategic Pipeline Assessment
  • 5.3. Osteoarthritis Pain Therapeutics Pipeline - Pipeline by Phases of Development
    • 5.3.1. Osteoarthritis Pain Therapeutics - Regulatory Filed Products
    • 5.3.2. Osteoarthritis Pain Therapeutics - Phase III Pipeline
    • 5.3.3. Osteoarthritis Pain Therapeutics - Phase II/III Pipeline
    • 5.3.4. Osteoarthritis Pain Therapeutics - Phase II Pipeline
    • 5.3.5. Osteoarthritis Pain Therapeutics - Phase I/II Pipeline
    • 5.3.6. Osteoarthritis Pain Therapeutics - Phase I Pipeline
    • 5.3.7. Osteoarthritis Pain Market - Discovery and Pre-Clinical Pipeline
    • 5.3.8. Technology Trends Analytic Framework
  • 5.4. Osteoarthritis Pain Therapeutics Market -Pipeline by Mechanism of Action
  • 5.5. Molecule Profile for Promising Drugs Under Development
    • 5.5.1. 2. PX
    • 5.5.2. Civanex
    • 5.5.3. BEMA
    • 5.5.4. CEP-33237
  • 5.6. Key Takeaway

6. Osteoarthritis Pain Therapeutics - Clinical Trials Mapping

  • 6.1. Clinical Trials by Region/Country (the US, EU5 and Japan)
  • 6.2. Clinical Trials by Phase
  • 6.3. Clinical Trials by Trial Status
  • 6.4. Prominent Sponsors
  • 6.5. Top Companies Participating in OA Pain Therapeutics Clinical Trials

7. Strategic Assessment

  • 7.1. Key Events Impacting the Future Market
  • 7.2. Osteoarthritis Pain Therapeutics: Implications for Future Market Competition

8. Osteoarthritis Pain Therapeutics - Future Players

  • 8.1. Introduction
  • 8.2. Company Profiles
    • 8.2.1. Winston Pharmaceuticals, Inc.
    • 8.2.2. Teva Pharmaceuticals
    • 8.2.3. Pfizer, Inc.
    • 8.2.4. SantoSolvo AS
    • 8.2.5. BioDelivery Sciences International, Inc.
    • 8.2.6. Savient Pharmaceuticals, Inc.
    • 8.2.7. Eli Lilly and Company
    • 8.2.8. Horizon Pharma
    • 8.2.9. Boehringer Ingelheim

9. Osteoarthritis Pain Therapeutics - Licensing and Partnership Deals

10. Osteoarthritis Pain Therapeutics - Appendix

  • 10.1. Market Definitions
  • 10.2. Abbreviations
  • 10.3. Bibliography
  • 10.4. Methodology
    • 10.4.1. Coverage
    • 10.4.2. Secondary Research
    • 10.4.3. Forecasting
    • 10.4.4. Primary Research
    • 10.4.5. Expert Panel Validation
  • 10.5. Contact Us
  • 10.6. Disclaimer

List of Tables

  • Table 1: Prevalence rates of Osteoarthritis Pain by Country/Region
  • Table 2: Prevalence Pool of Osteoarthritis Pain Patients in Seven Major Markets
  • Table 3: Clinical Features of Osteoarthritis Pain
  • Table 4: Classification Criteria for Osteoarthritis Pain
  • Table 5: Treatment Options for Osteoarthritis Pain
  • Table 6: Osteoarthritis Pain Therapeutics Market, Global, Revenue ($m), 2006-2011
  • Table 7: Osteoarthritis Pain Therapeutics Market, Global, Forecast ($m), 2011-2019
  • Table 8: Osteoarthritis Pain Therapeutics Market, The US, Revenue ($m), 2006-2011
  • Table 9: Osteoarthritis Pain Therapeutics Market, The US, Forecast ($m), 2011-2019
  • Table 10: Osteoarthritis Pain Therapeutics Market, France, Revenue ($m), 2006-2011
  • Table 11: Osteoarthritis Pain Therapeutics Market, France, Forecast ($m), 2011-2019
  • Table 12: Osteoarthritis Pain Therapeutics Market, Germany, Revenue ($m), 2006-2011
  • Table 13: Osteoarthritis Pain Therapeutics Market, Germany, Forecast ($m), 2011-2019
  • Table 14: Osteoarthritis Pain Therapeutics Market, Italy, Revenue ($m), 2006-2011
  • Table 15: Osteoarthritis Pain Therapeutics Market, Italy, Forecast ($m), 2011-2019
  • Table 16: Osteoarthritis Pain Therapeutics Market, Spain, Revenue ($m), 2006-2011
  • Table 17: Osteoarthritis Pain Therapeutics Market, Spain, Forecast ($m), 2011-2019
  • Table 18: Osteoarthritis Pain Therapeutics Market, The UK, Revenue ($m), 2006-2011
  • Table 19: Osteoarthritis Pain Therapeutics Market, The UK, Forecasts ($m), 2011-2019
  • Table 20: Osteoarthritis Pain Therapeutics Market, Japan, Revenue ($m), 2006-2011
  • Table 21: Osteoarthritis Pain Therapeutics Market, Japan, Forecasts ($m), 2011-2019
  • Table 22: Primary Efficacy Results for Synvisc: WOMAC Pain Score
  • Table 23: Adverse Events Associated with Synvisc
  • Table 24: Osteoarthritis Pain Therapeutics - Regulatory Filed Products, 2012
  • Table 25: Osteoarthritis Pain Therapeutics - Phase III Pipeline, 2012
  • Table 26: Osteoarthritis Pain Therapeutics - Phase II/III Pipeline, 2012
  • Table 27: Osteoarthritis Pain Therapeutics - Phase II Pipeline, 2012
  • Table 28: Osteoarthritis Pain Therapeutics - Phase I/II Pipeline, 2012
  • Table 29: Osteoarthritis Pain Therapeutics - Phase I Pipeline, 2012
  • Table 30: Osteoarthritis Pain Therapeutics - Preclinical and Discovery Phase Pipeline, 2012
  • Table 31: Osteoarthritis Pain Therapeutics - Clinical Trials by Country, 2012
  • Table 32: Osteoarthritis Pain Therapeutics - Clinical Trials by Phase, 2012
  • Table 33: Osteoarthritis Pain Therapeutics - Clinical Trials by Status, 2012
  • Table 34: Osteoarthritis Pain Therapeutics, Overall Sponsors, 2012
  • Table 35: Osteoarthritis Pain Therapeutics, Most Prominent Sponsors, 2012
  • Table 36: Osteoarthritis Pain Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2012
  • Table 37: Winston Pharmaceuticals, Inc. Osteoarthritis Pain Pipeline, 2012
  • Table 38: Osteoarthritis Pain Therapeutics, Cephalon Inc./Teva Pharmaceuticals, Osteoarthritis Pain Therapeutics Pipeline, 2012
  • Table 39: Pfizer, Osteoarthritis Pain Pipeline, 2011
  • Table 40: Osteoarthritis Pain Therapeutics, SantoSolve Pain Management Pipeline, 2012
  • Table 41: Osteoarthritis Pain Therapeutics, BioDelivery Sciences Pain Management Pipeline, 2012
  • Table 42: Licensing and Partnership Deals, 2008-2011

List of Figures

  • Figure 1: Differentiation between Normal Joint and Osteoarthritis Joint
  • Figure 2: Types of Osteoarthritis Pain
  • Figure 3: Knee Osteoarthritis
  • Figure 4: Osteoarthritis of Hand, Heberden's Nodes and Bouchard's Nodes
  • Figure 5: Hip Osteoarthritis
  • Figure 6: Examples of Disc Problems which Lead to Spine Osteoarthritis
  • Figure 7: Joints and Bones of the Foot and Ankle
  • Figure 8: Factors Affecting Degeneration of Cartilage
  • Figure 9: Key Opinion Leader Insights, Diagnosis of Osteoarthritis Pain in the US and the UK.
  • Figure 10: Progression of Osteoarthritis Pain Disease
  • Figure 11: Key Opinion Leader Insights, Guidelines for Osteoarthritis Pain in the US and the UK
  • Figure 12: Summary of Treatment Options for Osteoarthritis Pain
  • Figure 13: Key Opinion Leader Insights, Treatment of Osteoarthritis Pain in the US and the UK
  • Figure 14: Key Opinion Leader Insights, Pharmacological Treatment for Osteoarthritis Pain in the US and the UK
  • Figure 15: Management of Osteoarthritis of the Knee
  • Figure 16: Management of Osteoarthritis of the Hip
  • Figure 17: Referral Pathway for Osteoarthritis Pain
  • Figure 18: Key Opinion Leader Insights, Referral Pathway for Osteoarthritis Pain in the US and the UK
  • Figure 19: Osteoarthritis Pain Therapeutics Market, Global, Revenue ($m), 2006-2011
  • Figure 20: Osteoarthritis Pain Therapeutics Market, Global, Forecast ($m), 2011-2019
  • Figure 21: Osteoarthritis Pain Therapeutics Market, The US, Revenue ($m), 2006-2011
  • Figure 22: Osteoarthritis Pain Therapeutics Market, The US, Forecast ($m), 2011-2019
  • Figure 23: Osteoarthritis Pain Therapeutics Market, France, Revenue ($m), 2006-2011
  • Figure 24: Osteoarthritis Pain Therapeutics Market, France, Forecast ($m), 2011-2019
  • Figure 25: Osteoarthritis Pain Therapeutics Market, Germany , Revenue ($m), 2006-2011
  • Figure 26: Osteoarthritis Pain Therapeutics Market, Germany, Forecast ($m), 2011-2019
  • Figure 27: Osteoarthritis Pain Therapeutics Market, Italy, Revenue ($m), 2006-2011
  • Figure 28: Osteoarthritis Pain Therapeutics Market, Italy, Forecast ($m), 2011-2019
  • Figure 29: Osteoarthritis Pain Therapeutics Market, Spain, Revenue ($m), 2006-2011
  • Figure 30: Osteoarthritis Pain Therapeutics Market, Spain, Forecast ($m), 2011-2019
  • Figure 31: Osteoarthritis Pain Therapeutics Market, The UK, Revenue ($m), 2006-2011
  • Figure 32: Osteoarthritis Pain Therapeutics Market, The UK, Forecast ($m), 2011-2019
  • Figure 33: Osteoarthritis Pain Therapeutics Market, Japan, Revenue ($m), 2006-2011
  • Figure 34: Osteoarthritis Pain Therapeutics Market, Japan, Forecast ($m), 2011-2019
  • Figure 35: Key Opinion Leader Insights, Current Unmet Need for Osteoarthritis Pain in the US and the UK
  • Figure 36: Opportunity and Unmet Need in the Osteoarthritis Pain Therapeutics Market, 2011
  • Figure 37: Key Opinion Leader Insights, Limitations with the Currently Available Treatment Options for Osteoarthritis Pain in the US and the UK
  • Figure 38: Osteoarthritis Pain Therapeutics - Strategic Competitor Assessment, 2011
  • Figure 39: Key Opinion Leader Insights, Research for Future Treatment Options for Osteoarthritis Pain in the US and the UK
  • Figure 40: Osteoarthritis Pain Therapeutics - Pipeline by Phase of Development, 2012
  • Figure 41: Osteoarthritis Pain Therapeutics - Technology Trends Analytics Framework, 2012
  • Figure 42: Osteoarthritis Pain Therapeutics - Technology Trends Analytics Framework - Description, 2012
  • Figure 43: Osteoarthritis Pain Therapeutics - Pipeline by Mechanism of Action, 2012
  • Figure 44: Key Opinion Leader Insights, Target Profile Testing for Osteoarthritis Pain in the US and the UK
  • Figure 45: Osteoarthritis Pain Therapeutics - Clinical Trials by Country, 2012
  • Figure 46: Osteoarthritis Pain Therapeutics - Clinical Trials by Phase, 2012
  • Figure 47: Osteoarthritis Pain Therapeutics - Clinical Trials by Status, 2012
  • Figure 48: Osteoarthritis Pain Therapeutics - Overall Sponsors, 2012
  • Figure 49: Osteoarthritis Pain Therapeutics - Prominent Sponsors, 2012
  • Figure 50: Osteoarthritis Pain Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2012
  • Figure 51: Osteoarthritis Pain Therapeutics Market, Drivers and Barriers 2011
  • Figure 52: Implications for Future Market Competition in the Osteoarthritis Pain Market, 2011
  • Figure 53: Osteoarthritis Pain Therapeutics Market - Pipeline by Company, 2012
Show More
Pricing
Back to Top